SCHEMBL24377330

SCHEMBL24377330

C1=C(c2cccn3cnnc23)CCNC1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 8/20 0.44
SIGMAR1 Q99720 2/20 0.41
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
DRD2 P14416 1/20 0.40
ALOX15 P16050 1/20 0.40
HSD17B10 Q99714 1/20 0.40
KHK P50053 1/20 0.38
EED O75530 1/20 0.37
RBBP4 Q09028 1/20 0.37
SUZ12 Q15022 1/20 0.37
EZH2 Q15910 1/20 0.37
QDPR P09417 1/20 0.36
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
HTR6 P50406 1/20 0.35
SUV39H2 Q9H5I1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11029002 0.76 HTR2C (0.42) HTR2CSIGMAR1KDM4EALDH1A1MAPT
Hydrochloric Acid SCHEMBL16553729 0.70 JAK2 (0.50) HTR2CSIGMAR1KDM4EALDH1A1MAPT
SCHEMBL21077874 0.70 JAK1 (0.48) HTR2CSIGMAR1KDM4EALDH1A1MAPT
SCHEMBL16554303 0.70 JAK2 (0.50) HTR2CSIGMAR1KDM4EALDH1A1MAPT
SCHEMBL24377338 0.68 MAPT (0.39) KDM4EALDH1A1MAPTALOX15HSD17B10
SCHEMBL16565643 0.67 HTR2C (0.47) HTR2CSIGMAR1KDM4EALDH1A1MAPT
SCHEMBL24196984 0.66 HTR2C (0.50) HTR2CSIGMAR1KDM4EALDH1A1MAPT
SCHEMBL3774531 0.65 CCNT1 (0.56) HTR2CSIGMAR1KDM4EALDH1A1MAPT
SCHEMBL1366798 0.64 HTR2C (0.61) HTR2CSIGMAR1KDM4EALDH1A1MAPT
SCHEMBL4790197 0.64 HTR2C (0.61) HTR2CSIGMAR1KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382891-A1 GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF BLACKSMITH MEDICINES, INC. 2023-11-30 US disclosed
US-20230382891-A1 GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF BLACKSMITH MEDICINES, INC. 2023-11-30 US disclosed
US-20230382891-A1 GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF BLACKSMITH MEDICINES, INC. 2023-11-30 US disclosed
WO-2022086920-A1 GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF BLACKSMITH MEDICINES, INC. (US) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382891-A1 GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF QPCT, QPCTL, GLUL HTR2C 4668/4885SIGMAR1 4855/4885KDM4E 2763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.